Pacira BioSciences, Inc. reported a total revenue of $726.4 million for the fiscal year ending December 31, 2025, marking a 4% increase from $701.0 million in 2024. The growth was primarily driven by a 5% increase in net product sales of its flagship product, EXPAREL, which generated $575.1 million in sales, accounting for 79% of total revenues. The company also saw a 6% increase in sales of its iovera° product, while ZILRETTA sales decreased slightly by 1%. The overall gross margin improved to 79% from 76% in the previous year, attributed to lower inventory reserves and enhanced product costs.
In terms of strategic developments, Pacira made significant acquisitions, including GQ Bio Therapeutics in February 2025, which is expected to bolster its gene therapy pipeline, particularly the PCRX-201 program. The company also launched a new strategic growth plan called "5x30" aimed at expanding its patient reach and product revenues by 2030. As part of this initiative, Pacira reported reaching 2.5 million patients in 2025 and is on track for a five-percentage point improvement in gross margins through enhanced manufacturing efficiencies.
Operationally, Pacira's workforce consisted of 829 employees as of December 31, 2025, with a reduction of 71 employees due to the decommissioning of a smaller manufacturing suite, which is expected to lead to annual savings of approximately $13 million. The company has also expanded its manufacturing capabilities with new large-scale production facilities, which are anticipated to meet growing demand for its products. The company’s customer base remains concentrated, with three wholesalers accounting for 79% of total revenues.
Looking ahead, Pacira is focused on expanding the use of its products in additional surgical procedures and advancing its product pipeline, including ongoing clinical trials for PCRX-201. The company is also navigating challenges related to global economic conditions, including inflation and potential tariffs, which could impact its cost structure and operational efficiency. Despite these challenges, Pacira maintains a positive outlook, supported by its strategic initiatives and product development efforts aimed at addressing the opioid crisis through non-opioid pain management solutions.
About Pacira BioSciences, Inc.
Pacira BioSciences specializes in developing and commercializing non-opioid pain management therapies, including long-acting local anesthetics, corticosteroids, and nerve block devices. Its core products—EXPAREL, ZILRETTA, and iovera—serve surgical, orthopedic, and pain relief markets, emphasizing opioid reduction and enhanced recovery. The company leverages proprietary drug delivery and nerve modulation technologies to provide safe, effective, and targeted pain solutions for diverse patient populations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.